Sign up Australia
Proactive Investors - Run By Investors For Investors

Ergomed update underlines the potential of the company's PrimeVigilance unit

According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business
spreadsheet and calculator
The latest update from the firm showed the numbers are definitely stacking up revenues matching forecasts

PrimeVigilance was the stand-out performer for Ergomed Plc (LON:ERGO) in 2017, according to a leading healthcare analyst.

The verdict of Numis’s Stefan Hamill followed an upbeat end-of-year update from the group, which provides pharma services as well as helping develop drugs.

WATCH: Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal

According to Hamill, Ergomed’s drugs safety unit alone is worth as much as the whole business, which is currently valued at £84mln.

“In a sector where such growth is increasingly expensive for the more established mid-cap names we see Ergomed as a strong contender to become such a stock in the future,” Hamill said.

He reckons the shares, up 5.7% at 194p on Thursday, are worth 300p each, which would give the group a market capitalisation of £128mln.

Revenues in line with forecast

Earlier Ergomed said its services business posted total sales of £47mln for the period to December 31, up 21%, while net service revenues were ahead 35% at £39mln.

It won £54mln of new service contracts in 2017, up 29%, while the order backlog, a key indicator of future work, was £88mln.

“We enter 2018 in a position of strength, building on another year of strong top-line growth and continued execution on strategy,” said Ergomed chief executive Stephen Stamp.

According to broker Numis, the numbers were in line with forecasts.

It is predicting the company will post underlying earnings of £3.7mln for the year just gone, rising to £6.7mln in 2018.

Acquisition helped

Ergomed’s performance was boosted by the £5mln acquisition of PSR last September, which increased its interactions developers of orphan drugs.

Top line growth was driven primarily by the stellar contribution by the drug safety and medical information services (DS&MI) arm. The operation now represents approximately 57% of Ergomed’s total service revenues and its growth continues to outpace a fast-expanding market.

It is making a “drive for global leadership in this attractive market”, said CEO Stamp.

Hybrid model

Ergomed is a hybrid: a pharma services firm that also takes a stake in drugs during the development process.

That means as well as a profitable services business, it also has exposure to a number of new treatments making their way through clinical trials.

Ergomed has four partnership deals in the portfolio - with  Asarina, CEL-SCI, Ferrer and Modus.

View full ERGO profile View Profile

Ergomed PLC Timeline

Related Articles

little girl sneezing in a field
May 21 2018
The Phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety
syringe
June 21 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
1528098797_Biotech-lab.jpg
June 05 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use